Quest Diagnostics Inc (DGX) company profile
Close on Nov 17, 2026Market cap $28.20BP/E 25.6Yield –
About Quest Diagnostics
Services-Medical Laboratories, SIC 8071
Quest Diagnostics provides diagnostic information services and clinical testing solutions derived from routine, non-routine, and specialized laboratory tests. Its operations comprise two primary segments: Diagnostic Information Services, which delivers clinical lab testing, esoteric diagnostics, and diagnostic insights, and Diagnostic Solutions, which includes risk assessment for insurers and healthcare information technology offerings. The company serves physicians across numerous medical specialties, hospitals and health systems, accountable care organizations, health plans, employers, government agencies, pharmaceutical firms, and individual consumers seeking direct testing options.
Headquartered in Secaucus, New Jersey, Quest Diagnostics operates extensively across the United States alongside selective international facilities. Its domestic physical network includes approximately 2,400 patient service centers, around 8,000 total patient access points, laboratories, and specialized logistics assets featuring approximately 5,000 courier vehicles and 18 aircraft. In addition to broad U.S. coverage reaching approximately half of domestic physicians and hospitals annually, the company delivers reference testing to laboratory providers worldwide.
Summary of the business section of Quest Diagnostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Quest Diagnostics Inc
- Founded
- 1967
- Headquarters
- Secaucus, NJ
- Address
- 500 Plaza Drive 07094
- Phone
- (973) 520-2700
- Website
- questhealth.com
- Employees
- 57,000, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- DGX
- Exchange
- NYSE
- IPO date
- Dec 13, 1996
- Shares outstanding
- 110M, Oct 15, 2026
- Public float
- $20.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 21, 2005; 2-for-1, Jun 1, 2001
- SEC CIK
- 1022079
- CUSIP
- 74834L100
- ISIN
- US74834L1008
- FIGI
- BBG000BN84F3
- Share class FIGI
- BBG001S9GX43
- LEI
- 8MCWUBXQ0WE04KMXBX50
- EIN
- 16-1387862
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| J. E. Davis | CEO and President, Director | 122,423 |
| Michael J. Deppe | SVP, Corp. Controller & CAO | 35,916 |
| Patrick Plewman | SVP for Diagnostic Services | 14,684 |
| Subu Ramachandran | SVP, Regional Businesses | 2,832 |
| Mark E. Delaney | SVP & Chief Commercial Officer | 12,975 |
| Catherine T. Doherty | Executive Vice President | 76,501 |
| Sam Samad | Executive Vice President & CFO | 33,568 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 15,674 |
| Michael E. Prevoznik | SVP & General Counsel | 66,014 |
| Gary M. Pfeiffer | Director | 29,802 |
| Robert B. Carter | Director | 3,874 |
| Timothy L. Main | Director | 27,478 |
| Wright Lassiter III | Director | 10,329 |
| Vicky B. Gregg | Director | 18,449 |
| Timothy C. Wentworth | Director | 1,358 |
| Timothy M. Ring | Director | 31,140 |
| Luis Diaz | Director | 5,196 |
| Tracey Doi | Director | 7,748 |
| Denise M. Morrison | Director | 11,929 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $15.50M | $26.51M | $3.28M | $161 | $148 |
| FY2024 | $14.40M | $24.28M | $3.02M | $137 | $129 |
| FY2023 | $12.67M | $9.44M | $2.85M | $123 | $126 |
| FY2022 James EDavis | $11.88M | $12.71M | $3.39M | $136 | $124 |
| FY2022 Stephen HRucskwski | $15.68M | $9.82M | $3.39M | $136 | $124 |
| FY2022 Stephen HRusckowski | $15.68M | $9.82M | $3.39M | $136 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| James E. Davis Chairman, Chief Executive Officer and President | $1.25M | $8.76M | $3.00M | $2.21M | $279.90K | $15.50M | +8% |
| Sam A. Samad Executive Vice President and Chief Financial Officer | $693.27K | $2.19M | $749.74K | $710.36K | $82.81K | $4.43M | +9% |
| Catherine T. Doherty Executive Vice President, Regional Businesses | $643.27K | $1.68M | $574.88K | $615.18K | $49.94K | $3.56M | +8% |
| Michael E. Prevoznik Senior Vice President and General Counsel | $550.00K | $1.13M | $387.34K | $438.32K | $55.91K | $2.56M | +6% |
| Karthik Kuppusamy Senior Vice President, Clinical Solutions | $568.27K | $1.10M | $374.89K | $475.53K | $65.65K | $2.58M | +13% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we have nearly 57,000 employees globally (including LifeLabs’ approximately 6,800), of whom approximately 46,000 are full-time and the remainder are part-time or on-call.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?